Article

Sequential acquisition of tyrosine kinase domain mutations in a case of chronic myeloid leukemia: A dormant clone war against TKI

2022-01-31

Abstract excerpt

<title>Abstract</title> <p>The tyrosine kinase inhibitor (TKI) therapy has a high response rate in chronic myeloid leukemia (CML). However majority of patients relapse due to high mutation susceptibility of tyrosine kinase domain (TKD) of <italic>BCR/ABL</italic> fusion gene. We report a case of CML which was diagnosed and monitored for 10 years as per the ELN guidelines. Mutational analysis using Sanger sequenci...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 05a06f5a-97e3-5b8a-9aca-05cdf0fbaa2d
DOI: 10.21203/rs.3.rs-1300630/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Sequential acquisition of tyrosine kinase domain mutations in a case of chronic myeloid leukemia: A dormant clone war against TKIDOI 10.21203/rs.3.rs-1300630/v1Read

Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase.Semantic proximity Read

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.Semantic proximity Read

Emerging kinetics of BCR-ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure.Semantic proximity Read

Emergence of BCR-ABL kinase domain mutations associated with newly diagnosed chronic myeloid leukemia: a meta-analysis of clinical trials of tyrosine kinase inhibitors.Semantic proximity Read

Tyrosine kinase domain mutations in chronic myelogenous leukemia patients: A single center experience.Semantic proximity Read

Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy.Semantic proximity Read

Real-world data on the use of asciminib in chronic-phase chronic myeloid leukemia after two or more prior tyrosine kinase inhibitors: Results of the Turkish managed access program along with a literature review.Semantic proximity Read

Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.Semantic proximity Read

BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance.Semantic proximity Read

Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations.Semantic proximity Read

BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.Semantic proximity Read

[Origin of resistance to Imatinib mesylate: lessons learned from this experience].Semantic proximity Read